A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma

by | Jun 16, 2025 | Clinical Trials | 0 comments

​ Conditions: Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions: Drug: Cadonilimab; Drug: SOX chemotherapy

Sponsors: Akeso

Not yet recruiting Conditions: Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions: Drug: Cadonilimab; Drug: SOX chemotherapy
Sponsors: Akeso
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *